Announced Wed, 8 Apr · 16:01 IST

Munjal Mahendrabhai Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Below 50pctOwnership Changes View source PDF

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹552.00
prior close
₹552.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.0+0.8+0.1+4.0+3.3+7.1+6.9+6.0+10.0+16.3+26.7+15.1+10.2
Up moveDown movePending
AI summary

Lincoln Pharmaceuticals' Promoter/Promoter Group along with Persons Acting in Concert (PAC) hold 99,69,930 equity shares (49.78% of total capital) as of March 31, 2026. The disclosure explicitly states that no encumbrance of shares was made by the promoter group during Financial Year 2025-2026. The filing includes 29 entities in the promoter group including family members and related entities like Downtown Finance Pvt Ltd and Sunmed Corporation LLP. The holding is just below the 50% threshold, which is a notable position for the controlling shareholders.

Likely market impact

The promoter holding below 50% may signal potential dilution or past share sales. However, the explicit declaration of no encumbrance is positive as it rules out pledged shares risk. Shareholders should note this is an annual compliance filing, not a transaction disclosure.